Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
, 22 (1), 18-22

Memantine Reverses Social Withdrawal Induced by Ketamine in Rats

Affiliations

Memantine Reverses Social Withdrawal Induced by Ketamine in Rats

Ezequiel Uribe et al. Exp Neurobiol.

Abstract

The objective of this study was to determine the effect of memantine on schizophrenia-like symptoms in a ketamine-induced social withdrawal model in rats. We examined therapeutic effects of memantine, an NMDA antagonist, and haloperidol, a classic antipsychotic drug, on this behavioral model. Administration of memantine (10 or 15 mg·kg(-1)) significantly reduced ketamine-induced social withdrawal, and this effect was more effective than that of haloperidol (0.25 mg·kg(-1)) by restoring the social interaction between rats with no modification in general motor activity. These results suggest that memantine could have a therapeutic potential for schizophrenia.

Keywords: NMDA; experimental psychosis; haloperidol; ketamine; social interaction test.

Figures

Fig. 1
Fig. 1
A (n: 20) B (n: 20), A1 (n: 5): memantine 10 mg·kg-1, A2 (n: 5): memantine 10 mg·kg-1, A3 (n: 5): haloperidol 0.25 mg·kg-1, A4: saline.
Fig. 2
Fig. 2
Distance between rats for treatment groups during the social interaction test. Distance between rats was expressed as means±SD in cm. Treatment groups: (A) rats without pharmacological intervention, (B) 5 days after ketamine withdrawal, (C) 10 mg·kg-1 memantine after ketamine withdrawal, (D) saline after ketamine withdrawal, (E) 15 mg·kg-1 memantine after ketamine withdrawal, (F) 0.25 mg·kg-1 haloperidol after ketamine withdrawal.
Fig. 3
Fig. 3
Average speed for treatment groups during the social interaction test. Average speed was expressed as means±SD in cm·s-1. Treatment groups: (A) rats without pharmacological intervention, (B) 5 days after ketamine withdrawal, (C) 10 mg·kg-1 memantine after ketamine withdrawal , (D) placebo after ketamine withdrawal, (E) 15 mg·kg-1 memantina after ketamine withdrawal, (F) 0,25 mg·kg-1 haloperidol after ketamine withdrawal.

Similar articles

See all similar articles

Cited by 10 PubMed Central articles

See all "Cited by" articles

References

    1. Lehman AF, Lieberman JA, Dixon LB, McGlashan TH, Miller AL, Perkins DO, Kreyenbuhl J American Psychiatric Association; Steering Committee on Practice Guidelines. Practice guideline for the treatment of patients with schizophrenia, second edition. Am J Psychiatry. 2004;161:1–56. - PubMed
    1. Krystal JH, Karper LP, Seibyl JP, Freeman GK, Delaney R, Bremner JD, Heninger GR, Bowers MB, Jr, Charney DS. Subanesthetic effects of the noncompetitive NMDA antagonist, ketamine, in humans. Psychotomimetic, perceptual, cognitive, and neuroendocrine responses. Arch Gen Psychiatry. 1994;51:199–214. - PubMed
    1. Becker A, Grecksch G, Bernstein HG, Höllt V, Bogerts B. Social behaviour in rats lesioned with ibotenic acid in the hippocampus: quantitative and qualitative analysis. Psychopharmacology (Berl) 1999;144:333–338. - PubMed
    1. Keilhoff G, Becker A, Grecksch G, Wolf G, Bernstein HG. Repeated application of ketamine to rats induces changes in the hippocampal expression of parvalbumin, neuronal nitric oxide synthase and cFOS similar to those found in human schizophrenia. Neuroscience. 2004;126:591–598. - PubMed
    1. Homayoun H, Moghaddam B. NMDA receptor hypofunction produces opposite effects on prefrontal cortex interneurons and pyramidal neurons. J Neurosci. 2007;27:11496–11500. - PMC - PubMed
Feedback